Windtree reports positive Phase 2b study on heart failure therapy
WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology firm specializing in the development of therapies for critical diseases and currently valued at $1.44 million market ...
Heart attack or just chest pain? Know crucial difference and best treatment option that could save your life
Doctor reveals the #1 mistake people make during a heart attack and suggest the best treatment option that can save your life ...
Windtree Therapeutics announces istaroxime presentation on Phase 2b study
Windtree Therapeutics (WINT) announced that an istaroxime presentation featuring the positive Phase 2b SEISMiC study was given on February 11, ...
PharmiWeb2d
Key Innovations Driving Growth in the Cardiogenic Shock Treatment Market
Explore the latest innovations in cardiogenic shock treatment, including advances in mechanical circulatory support devices, ...
Too Old to Operate6d
Corticosteroid Administration and Mortality in Cardiogenic Shock
The following is a summary of “Corticosteroids in Cardiogenic Shock: A Retrospective Analysis of the Medical Information Mart ...